We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AUGTYRO (Bristol-Myers Squibb Australia Pty Ltd)
Product name
AUGTYRO
Date registered
Evaluation commenced
Decision date
Approval time
245 (255 working days)
Active ingredients
repotrectinib
Registration type
NCE/ NBE
Indication
AUGTYRO, as monotherapy, is indicated for the treatment of adult patients with ROS1- positive locally advanced or metastatic non-small cell lung cancer (NSCLC).